ReviewMarine drugs2019
Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials.
Review in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 137 citations in OpenAlex.
- Deep learning-based structural prediction (AlphaFold 3) of shrimp IMNV RdRp and identification of seaweed-derived metabolites for antiviral intervention in aquaculture.Virus research · 2026Article
- Laurinterol, the MainMarine drugs · 2026Review
- Pro-myogenic and anti-atrophic effects of Padina arborescens extract through Akt/mTOR signaling in dexamethasone-induced C2C12 cells and zebrafish model.In vitro cellular & developmental biology. Animal · 2026Article
- Potential Role of Brown Macroalgae on Pig Health: A Review.ACS nutrition science · 2026Review
- Engineering programmable CAR and antigen pairing via drug-gated light activation.Nature communications · 2026Article
- Molecular insights into the anticancer properties of dieckol: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Mini-review: red seaweedPeerJ · 2026Review
- Marine Fungal Metabolites: A Promising Source for Antibiofilm Compounds.Molecules (Basel, Switzerland) · 2025Review
- ExploringAquaculture nutrition · 2025Article
- Abiotic Factors Modulating Metabolite Composition in Brown Algae (Phaeophyceae): Ecological Impacts and Opportunities for Bioprospecting of Bioactive Compounds.Marine drugs · 2024Review
- Impact of Ultrasound- and Microwave-Assisted Extraction on Bioactive Compounds and Biological Activities ofMarine drugs · 2024Article
- Review
- Natural Bioactive Compounds from Macroalgae and Microalgae for the Treatment of Alzheimer's Disease: A Review.The Yale journal of biology and medicine · 2024Review
- Seaweeds as Nutraceutical Elements and Drugs for Diabetes Mellitus: Future Perspectives.Marine drugs · 2024Review
- From Ocean to Medicine: Harnessing Seaweed's Potential for Drug Development.International journal of molecular sciences · 2024Review
- Potential Application of Marine Algae and Their Bioactive Metabolites in Brain Disease Treatment: Pharmacognosy and Pharmacology Insights for Therapeutic Advances.Brain sciences · 2023Review
- Green algaeNarra J · 2023Article
- Rapid and cost-efficient microplate assay for the accurate quantification of total phenolics in seaweeds.Food chemistry. Molecular sciences · 2023Article
- Applications of Antioxidant Secondary Metabolites ofMarine drugs · 2023Review
- Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macroalgae are increasingly viewed as a source of secondary metabolites with great potential for the development of new drugs. In this development, in vitro studies are only the first step in a long process, while in vivo studies and clinical trials are the most revealing stages of the true potential and limitations that a given metabolite may have as a new drug. This literature review aims to give a critical overview of the secondary metabolites that reveal the most interesting results in these two steps. Phlorotannins show great pharmaceutical potential in in vivo models and, among the several examples, the anti-dyslipidemia activity of dieckol must be highlighted because it was more effective than lovastatin in an in vivo model. The IRLIIVLMPILMA tridecapeptide that exhibits an in vivo level of activity similar to the hypotensive clinical drug captopril should still be stressed, as well as griffithsin which showed such stunning results over a variety of animal models and which will probably move onto clinical trials soon. Regarding clinical trials, studies with pure algal metabolites are scarce, limited to those carried out with kahalalide F and fucoxanthin. The majority of clinical trials currently aim to ascertain the effect of algae consumption, as extracts or fractions, on obesity and diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.